Eliano Pio Navarese
Overview
Explore the profile of Eliano Pio Navarese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
1330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng H, Vidili G, Casu G, Navarese E, Sechi L, Chen Y
Front Toxicol
. 2024 Oct;
6:1479292.
PMID: 39449982
With the widespread use of plastic products and the increase in waste, microplastics and nanoplastics (MNPs) have become an important issue in global environmental pollution. In recent years, an increasing...
2.
Zheng H, Sechi L, Navarese E, Casu G, Vidili G
Cardiovasc Diabetol
. 2024 Sep;
23(1):346.
PMID: 39342178
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease...
3.
Talanas G, Laconi A, Kereiakes D, Merella P, Reardon M, Spano A, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
3(7):102143.
PMID: 39131994
Background: We aimed to perform a meta-analysis of randomized trials comparing long-term outcomes of patients undergoing transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) for severe aortic...
4.
Ostrowska M, Kasprzak M, Stolarek W, Grzelakowska K, Krys J, Kubica A, et al.
Rev Cardiovasc Med
. 2024 Jul;
23(9):292.
PMID: 39077718
Background: The coronavirus disease-2019 (COVID-19) pandemic is surging across Poland, leading to many direct deaths and underestimated collateral damage. We aimed to compare the influence of the COVID-19 pandemic on...
5.
Galli M, Laudani C, Occhipinti G, Spagnolo M, Gragnano F, DAmario D, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Jul;
10(7):588-598.
PMID: 39054275
Background: P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy (DAPT) may balance ischaemic and bleeding risks in patients with acute coronary syndrome (ACS). However, it remains uncertain...
6.
Casula M, Casu G, Talanas G, Spano A, Tantry U, Bilotta F, et al.
Curr Probl Cardiol
. 2024 May;
49(8):102635.
PMID: 38750991
Background: Debates persist regarding the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in coronary artery disease (CAD). Recent trials have introduced a novel approach involving...
7.
Micheluzzi V, Navarese E, Merella P, Talanas G, Viola G, Bandino S, et al.
Front Cardiovasc Med
. 2024 Apr;
11:1356361.
PMID: 38633842
Virtual reality offers a multisensory experience to patients, allowing them to hear, watch, and interact in a virtual environment. Immersive virtual reality is particularly suitable for the purpose of completely...
8.
Galli M, Costa F, Navarese E
Eur Heart J Cardiovasc Pharmacother
. 2024 Mar;
10(4):267-269.
PMID: 38458235
No abstract available.
9.
Landi A, Aboyans V, Angiolillo D, Atar D, Capodanno D, Fox K, et al.
Eur Heart J Acute Cardiovasc Care
. 2024 Jan;
13(1):173-180.
PMID: 38170562
Antithrombotic therapy represents the cornerstone of the pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration of antithrombotic therapy is still matter of debate requiring...
10.
Kubica J, Adamski P, Gajda R, Gasior M, Gierlotka M, Gil R, et al.
Cardiol J
. 2023 Jul;
30(4):502-505.
PMID: 37401419
No abstract available.